The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 18, 2017

Filed:

Jan. 27, 2012
Applicants:

Larry Glass, Takoma Park, MD (US);

Michael John Bickerdike, Auckland, NZ;

Michael Frederick Snape, Thames Ditton, GB;

Inventors:

Larry Glass, Takoma Park, MD (US);

Michael John Bickerdike, Auckland, NZ;

Michael Frederick Snape, Thames Ditton, GB;

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); C07K 5/062 (2006.01); A61K 31/401 (2006.01); A61K 45/06 (2006.01); A61K 38/06 (2006.01); A61K 9/127 (2006.01); A61K 38/05 (2006.01); A61K 9/06 (2006.01); A61K 9/107 (2006.01);
U.S. Cl.
CPC ...
C07K 5/06026 (2013.01); A61K 9/127 (2013.01); A61K 31/401 (2013.01); A61K 38/05 (2013.01); A61K 38/06 (2013.01); A61K 45/06 (2013.01); A61K 9/0019 (2013.01); A61K 9/0085 (2013.01); A61K 9/06 (2013.01); A61K 9/107 (2013.01);
Abstract

This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyl-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum Disorders include Autism, Autistic Disorder Asperger Syndrome, Childhood Disintegrative Disorder, Pervasive Developmental Disorder—Not Otherwise Specified (PDD-NOS), Fragile X Syndrome, and Rett Syndrome. Compositions containing compounds include water-soluble formulations, water-in-oil micro-emulsions, water-in-oil coarse emulsions, water-in-oil liquid crystals, nanocapsules, tablets, and orally administered gels. The compounds and compositions of this invention can be administered intravenously, intraventricularly, parenterally, or orally, and can be effective in treating neurodegeneration, promoting neurological function, treating seizure activity and other symptoms of ASD, and can prolong life in animals including human beings having Autism Spectrum Disorders.


Find Patent Forward Citations

Loading…